Toronto, ON; July 19, 2023 – Proteocyte AI is pleased to announce the the addition of Edward Gudaitis as a Business Advisor.
Ed is an experienced life sciences and pharmaceutical leader with over 28 years of senior leadership experience across multiple stages of pharmaceutical commercialization and therapeutic areas covering multiple geographies.
Since 2018, Mr. Gudaitis has been President and CEO of publicaly traded Acerus Pharmaceuticals Corporation Inc. Prior to Acerus, he spent over a decade at Gilead Sciences Inc. where he was responsible for starting up Gilead’s operations in Canada and for leading the commercial launch of two significant HIV products in the US market.
In addition, Ed spent over 10 years at Hoffmann-La Roche and has extensive experience in specialty markets such as Oncology, Hepatitis, HIV, CNS, Urology, and Transplantation.
Ed’s arrival marks the latest addition to Proteocyte’s continued growth, as the company builds out a highly experienced and knowledgeable team of advisors to complement its core management and staff.
John Jordan, Chief Financial Officer at Proteocyte: “The addition of Ed Gudaitis to the Proteocyte team of external advisors is a significant step forward as we continue the roll-out of STRATICYTE™, our oral cancer risk assessment product. Ed’s strengths in terms of his extensive business network and knowledge of the commercialization path represents a big win for us.”
Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, STRATICYTE™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.